EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials

Huilin Tang iD, Weihan Chen iD, Jiang Bian iD, LaToya J O'Neal, Daniel T Lackland iD, Desmond A Schatz iD, Jingchuan Guo iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.026791 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Huilin Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy Gainesville FL USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hispanic populations are more likely to develop diabetes and its related diseases than non‐Hispanic White populations. Little evidence exists to support whether the cardiovascular and renal benefits of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists are generalizable to the Hispanic populations. Methods and Results We included the cardiovascular and renal outcome trials (up to March 2021) that reported the major adverse cardiovascular events (MACEs), cardiovascular death/hospitalization for heart failure, and composite renal outcomes by ethnicity in individuals with type 2 diabetes (T2D), calculated pooled hazard ratios (HRs) with 95% CIs using fixed‐effects models, and tested the differences between Hispanic and non‐Hispanic populations ( P for interaction [ P interaction ]). In 3 sodium‐glucose cotransporter 2 inhibitor trials, there was a statistically significant difference between Hispanic (HR, 0.70 [95% CI, 0.54–0.91]) and non‐Hispanic (HR, 0.96 [95% CI, 0.86–1.07]) groups in treatment effects on MACE risk ( P interaction =0.03), except for risks of cardiovascular death/hospitalization for heart failure ( P interaction =0.46) and composite renal outcome ( P interaction =0.31). In 5 glucagon‐like peptide‐1 receptor agonist trials, there was no statistically significant difference in treatment effect on MACE risk between Hispanic (HR, 0.82 [95% CI, 0.70–0.96]) and non‐Hispanic (HR, 0.92 [95% CI, 0.84–1.00]) populations ( P interaction =0.22). In 3 dipeptidyl peptidase‐4 inhibitor trials, the HR for MACE risk appeared greater in Hispanic (HR, 1.15 [95% CI, 0.98–1.35]) than non‐Hispanic (HR, 0.96 [95% CI, 0.88–1.04]) populations ( P interaction =0.045).

Conclusions

Compared with non‐Hispanic individuals, Hispanic individuals with T2D appeared to obtain a greater benefit of lowered MACE risk with sodium‐glucose cotransporter 2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesHeart FailureHumansGlucoseHypoglycemic AgentsSodiumGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Hispanic populationcardiovascular outcomesglucose‐lowering drugsrenal outcomes

Substanzen

GlucoseSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodiumGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy University of Florida College of Pharmacy Gainesville FL USA.
  • Department of Health Outcomes and Biomedical Informatics College of Medicine, University of Florida Gainesville FL USA.
  • Department of Family, Youth and Community Sciences Institute of Food and Agricultural Sciences, University of Florida Gainesville FL USA.
  • Department of Neurology Medical University of South Carolina Charleston SC USA.
  • Division of Endocrinology Department of Pediatrics University of Florida College of Medicine Gainesville FL USA.
  • Center for Drug Evaluation and Safety University of Florida Gainesville FL USA.

ORCID-Profile: Huilin Tang, Weihan Chen, Jiang Bian, Daniel T Lackland, Desmond A Schatz, Jingchuan Guo

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Tang, H., Chen, W., Bian, J., O'Neal, L. J., Lackland, D. T., Schatz, D. A., & Guo, J. (2023). Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.026791

Vancouver

Tang H, Chen W, Bian J, O'Neal LJ, Lackland DT, Schatz DA, et al. Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.026791

BibTeX
@article{Tang2023,
  author = {Tang, Huilin and Chen, Weihan and Bian, Jiang and O'Neal, LaToya J and Lackland, Daniel T and Schatz, Desmond A and Guo, Jingchuan},
  title = {Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose‐Lowering Drugs: A Meta‐Analysis of Randomized Outcome Trials},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.026791}
}
Kostenlos starten →